Investors Target PROCEPT BioRobotics in Securities Fraud Class Action Over Stock Decline

Serious Class Action Filed Against PROCEPT BioRobotics Corporation

On August 12, 2026, an alert was issued to investors by Hagens Berman Sobol Shapiro LLP regarding a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT). This action is rooted in substantial allegations of securities fraud connected to undisclosed inventory issues that have led to a staggering 48% decline in stock value since August 2025. The class period of the lawsuit spans from February 28, 2024, to February 25, 2026.

The Allegations

The lawsuit acknowledges growing concerns surrounding PROCEPT's business practices, particularly focusing on the sales of its single-use handpiece, an integral part of its innovative Aquablation therapy aimed at treating enlarged prostate. The allegations suggest that PROCEPT intentionally misled investors regarding its performance by promoting inflated sales figures derived from strategic bulk discounts.

During this class period, the company reportedly encouraged excessive orders that exceeded clients' actual procedural needs. By doing so, PROCEPT allegedly manipulated sales to appear stronger than they truly were, thus giving misleading signals to investors about the company's operational health.

The consequences of these actions began to unravel, causing the stock price to plummet after a series of troubling disclosures regarding the company’s financial standings. On August 6, 2025, for instance, PROCEPT reported dismal Q2 results that failed to meet market expectations, raising red flags about its inventory practices.

Consequences of the Mismanagement

Further revelations arrived with the release of Q3 2025 results, which also fell short of projections, leading to significant downward adjustments in annual handpiece sales forecasts. Notably, during the earnings call, management candidly admitted to mismanagement concerning customer inventories, making it evident that clients were carrying an excess of handpieces.

In a final blow, February 25, 2026, brought yet more damning news: PROCEPT disclosed that U.S. handpiece sales had outpaced actual medical procedures for numerous quarters, indicating an alarming overstock scenario. This realization unveiled a staggering overage of over 10,000 units that had severely impacted the company's revenue streams.

The late revelation of such dire inventory practices led to a significant loss of approximately $22.06 per share, an unfortunate decline that left many investors reeling from losses incurred during their investments in the company.

Seeking Justice

Hagens Berman, a prominent law firm specializing in securities class actions, is committed to uncovering whether PROCEPT intentionally misled investors to temporarily bolster its stock price. They urge individuals who suffered losses due to this situation to come forward and share their stories.

The lead plaintiff deadline is set for September 22, 2026, and investors are encouraged to act promptly to ensure their voices are heard. Those possessing insight into the matter or seeking to contribute to the investigation can reach out to the firm's dedicated legal team for support.

For further information on this case and to learn about the ongoing investigations into PROCEPT BioRobotics Corporation, interested parties can visit Hagens Berman’s official website.

Whistleblower Opportunities

The firm extends an invitation to whistleblowers who may hold non-public information regarding PROCEPT’s operations to come forward. By participating in the SEC Whistleblower program, individuals may qualify for financial rewards for information leading to significant enforcement action against the company.

In conclusion, the turn of events surrounding PROCEPT BioRobotics underscores the critical nature of transparency and honesty in corporate communications. Investors deserve accurate information to make informed decisions, and this ongoing litigation aims to pursue accountability and justice for those affected by these alleged fraudulent activities.